Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Healthtrust
Baxter
Cerilliant
US Department of Justice
Citi
Harvard Business School
Chubb
Express Scripts

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,927,607

« Back to Dashboard

Which drugs does patent 8,927,607 protect, and when does it expire?

Patent 8,927,607 protects MITIGARE and is included in one NDA.
Summary for Patent: 8,927,607
Title:Methods of colchicine administration
Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
Inventor(s): Ducharme; Murray (St Laurent, CA)
Assignee: Hikma Pharmaceuticals LLC (Amman, JO)
Application Number:13/973,897
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,927,607

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hikma Intl Pharms MITIGARE colchicine CAPSULE;ORAL 204820-001 Sep 26, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,927,607

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,789,108 Methods of colchicine administration ➤ Sign Up
9,399,036 Methods of colchicine administration ➤ Sign Up
9,555,029 Methods of colchicine administration ➤ Sign Up
9,675,613 Methods of colchicine administration ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chinese Patent Office
Moodys
US Army
Julphar
Merck
Mallinckrodt
Queensland Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot